# A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Source: https://onco.cc/trials/nct07519772/  
OnCo record `nct07519772` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MK-1045 in non-hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) is a phase 1/2 interventional study registered as NCT07519772 by Merck Sharp & Dohme LLC, with 280 participants planned, started 2026-05-03 and due to reach its primary completion in 2030-07-01. Interventions recorded: MK-1045. Conditions listed: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07519772
- Phase: 1/2
- Setting: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT07519772: https://clinicaltrials.gov/study/NCT07519772

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [MK-1045](https://onco.cc/drugs/mk-1045/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07519772.json